Bronchogen

ExperimentalKhavinson bioregulator / researchExperimental

Also known as: Lung bioregulator, AEDL, ADEL

Bronchogen (also called Lung bioregulator or AEDL) is a khavinson bioregulator. Bronchogen is a synthetic tetrapeptide, written Ala-Glu-Asp-Leu in most papers and Ala-Asp-Glu-Leu in some, in the Khavinson bioregulator series associated with bronchial and pulmonary tissue.

Calculate Dose

For research use only.

Key Facts

CAS: —
Molecular Weight (MW): 446.46 g/mol
Half-life: Not established (small tripeptide)
FDA status: Not Approved
Evidence level: Insufficient Evidence
Human dose established: No
Administration Route: Not established in humans
Frequency: Not established in humans
Last updated: Nov 7, 2026
Reviewed: Nov 7, 2026
Targets: Bronchial epithelium (proposed)

Vendor price snapshot

Each vendor counts once, at the median price per mg of its own listings; the typical range is the middle half of vendors. From public vendor listings collected between Oct 2026 and Nov 2026, so confirm the live price on the vendor site. Peptide Library does not sell peptides.

Vendors listing this peptide: 7
Listed offers: 9
Median price per mg: $3.32/mg; Typical $2.85–$5.22/mg

Open calculator · Compare vendors

Research summary

Short synthetic tetrapeptide marketed as a Khavinson bronchial/lung bioregulator. Papers give its sequence as Ala-Glu-Asp-Leu (AEDL) or Ala-Asp-Glu-Leu (ADEL). Russian literature only; not FDA-approved.

Research evidence

Regulatory review (FDA label)None in reviewed sources
Controlled human trialsNone in reviewed sources
Early or uncontrolled human studiesNone in reviewed sources
Lab & animal studies2 reviewed sources

How it works

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

Peptide Library's Bronchogen profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.

Bronchogen dosage: no established human dose

Bronchogen has no established human dosage. It is a synthetic tetrapeptide from the Khavinson bioregulator series; most indexed papers give its sequence as Ala-Glu-Asp-Leu (AEDL), and some as Ala-Asp-Glu-Leu (ADEL). No trial of it is registered on ClinicalTrials.gov and no human study is indexed. Its evidence is cell-culture work and a rat model of obstructive lung disease, and those abstracts do not state the doses used.

Insufficient Evidence

No established human dosage.

Human clinical evidence: None identified.

Preclinical research: Bronchogen is a short synthetic peptide from the Russian bioregulator research school that developed epitalon. Its literature is a handful of cell-culture, DNA-binding and rat studies, mostly from that school. The indexed abstracts give no doses, and no study has given it to people. Nothing here establishes a human dose, route or interval.

Animal dosing is not converted into a human dose anywhere on this page. Where research figures appear below, they are reported as studied, not recommended.

Dosage evidence summary for Bronchogen
Human dosing established	No
Route	Not established in humans
Evidence level	Insufficient Evidence
Last reviewed	2026-11-07

Preclinical and analog research

Not human dosing evidence. Listed for completeness and never extrapolated to a human dose.

Research-reported dosing for Bronchogen, one row per studied regimen
Study / context	Population	Dose	Route	Frequency	Duration	Outcome studied	Source
Preclinical — rat model of chronic obstructive pulmonary disease (2015)Preclinical · Animal study	Rats with lung disease induced by 60 days of intermittent nitrogen dioxide exposure	Not stated in the indexed abstract (non-human)	Not stated in the indexed abstract	—	1 month	Less remodelling of the bronchial epithelium and lung tissue, more secretory IgA and less neutrophilic inflammation	Modulating Effect of Peptide Therapy on the Morphofunctional State of Bronchial Epithelium in Rats with Obstructive Lung Pathology. Bull Exp Biol Med. 2015.
In vitro — the peptide written as ADEL, in human embryonic bronchial epithelial cell cultures (2014)Preclinical · Preclinical cell-culture study	Human embryonic bronchial epithelial cell cultures at the 1st, 7th and 14th passage	Concentration not stated in the indexed abstract; added to cell culture, not given to a person	In vitro, added to culture medium	—	—	Changes in proliferation and differentiation proteins and genes, strongest in later-passage ("old") cultures; DNA binding shown in solution	Peptide regulation of gene expression and protein synthesis in bronchial epithelium. Lung. 2014.

Where sources disagree

Bronchogen is sold with protocols, but no registered trial or indexed human study reports a dose for it.
Its sequence is written two ways in the same group's papers: most give Ala-Glu-Asp-Leu (AEDL), while a 2010 DNA study and a 2014 bronchial-cell study give Ala-Asp-Glu-Leu (ADEL). These are different peptides, and the indexed record does not say which one any product contains.
The lung-protection claims come from a rat model and cell cultures, not from a study in people.

Reconstitution

Common research vial sizes: 10 mg, 20 mg.

Reconstitution arithmetic for Bronchogen
Vial	Bacteriostatic water	Concentration	Per 0.01 mL
10 mg	2 mL	5 mg/mL	50 mcg per 0.01 mL
20 mg	2 mL	10 mg/mL	100 mcg per 0.01 mL

These figures are arithmetic only — they convert a vial and a volume into a concentration. They are not a recommendation to take any dose.

Calculate reconstitution & dose →

Sequence & molecular data

Sequence and molecular data for Bronchogen
Molecular formula	C18H30N4O9
Molecular weight	446.46 g/mol
Half-life	Not established (small tripeptide)
Appearance	White lyophilized powder
Formulation	Lyophilized Powder
PubChem CID	11690869

Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.

Science

Mechanism of Action

Bronchogen is a synthetic tetrapeptide, written Ala-Glu-Asp-Leu in most papers and Ala-Asp-Glu-Leu in some, in the Khavinson bioregulator series associated with bronchial and pulmonary tissue. The proposed mechanism common to that series is that short peptides enter the cell nucleus and interact directly with specific promoter regions of DNA, altering transcription of tissue-relevant genes — a form of peptide-directed epigenetic regulation. Supporting work consists largely of cytogenetic and cell-culture studies published by one research group, predominantly in Russian-language journals. The mechanism has not been independently established in Western controlled research, and no clinical trials support the tissue-specific claims.

Origin

Synthetic short peptide from the Khavinson bioregulator series.

Targets

Bronchial epithelium (proposed)

Studies

Research statistics

14 PubMed publications · 0.0% human clinical research · 1 registered trial

Counts of published research through 2026-11-01, not evidence that it works. Publications by year, study types and trials · How publications are counted

Regulatory & research status

Bronchogen is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.

Regulatory and research status for Bronchogen
FDA status	Not Approved
Availability	Research-Only
WADA (sport)	Unknown / Not Listed
Library classification	Research-Only

How FDA approval, compounding and research-only status differ

Benefits

Respiratory-epithelium research (historical RU literature)

Bronchogen side effects

Bronchogen has no controlled human safety data. The effects below are reported, not established, and absence from the list is not evidence of safety.

Side Effects

Not characterized in modern RCTs

Storage & stability

Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.

Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.

Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.

Read the full guide: how to store peptides before and after reconstitution →

Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.

Bronchogen: frequently asked questions

What is Bronchogen?

Short peptide marketed as a Khavinson bronchial/lung bioregulator (often AEDL). Russian literature only; not FDA-approved.

How does Bronchogen work?

Bronchogen is Ala-Glu-Asp-Leu, a synthetic tetrapeptide in the Khavinson bioregulator series associated with bronchial and pulmonary tissue. The proposed mechanism common to that series is that short peptides enter the cell nucleus and interact directly with specific promoter regions of DNA, altering transcription of tissue-relevant genes — a form of peptide-directed epigenetic regulation.

Is Bronchogen FDA approved?

No. Bronchogen is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.

What is the half-life of Bronchogen?

Reported half-life for Bronchogen is Not established (small tripeptide). Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.

What peptides are similar to Bronchogen?

Compounds most often compared with Bronchogen include Bonomarlot, Cardiogen, Cartalax and Cerluten. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.

References

Related research, comparisons & guides

Related peptides

Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Nov 7, 2026 · Version 4

This Bronchogen profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error

Track Bronchogen research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →